EUCTR2018-003831-31-ES进行中（未招募）1 期
A multicenter, open-label Phase 2 study with escalating doses of MS1819-SD on top of a stable dose of PPEs, to investigate the efficacy and safety of this combination for the compensation of severe exocrine pancreatic insufficiency in CF patients not fully compensated with only PPEs
AzurRx0 个研究点目标入组 24 人开始时间: 2019年12月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed and dated informed consent form.
- •2.Age > or = 12 years at the time of screening
- •3.Male or female.
- •4.Under stable dose of PPE = 1 month. Stable dose is defined as dose of medication not changed during this time period and the medication must be commercially available and be administered in the recommended dose range.
- •5.A nutritional status as defined by:
- •a.BMI < or = 22.0 kg/m2 for female patients
- •b.BMI < or = 23.0 kg/m2 for male patients
- •c.BMI < or = 50th percentile for patients 12 to < 18 years of age.
- •6.Cystic fibrosis (CF), based on at least 2 clinical features consistent with CF in the opinion of the investigator and a sweat chloride concentration > 60 mmol/L by pilocarpine iontophoresis.
- •7.Fecal pancreatic elastase-1 < 100 µg/g of stools at screening.
- •8.Baseline CFA < 80% with a maximum daily dose of 10,000 lipase units/kg/day.
- •9.Clinically stable with no documented evidence of significant respiratory symptoms that would require administration of intravenous antibiotics, oxygen supplementation, or hospitalization within the 30 days of screening.
- •10.Male and female patients, if of childbearing potential, must use a reliable method of contraception during the study. A reliable method of birth control is defined as one of the following: oral or injectable contraceptives, intrauterine device, contraceptive implants, tubal ligation, hysterectomy, or a double-barrier method (diaphragm with spermicidal foam or jelly, or a condom), abstinence or vasectomy. Periodic abstinence (calendar, symptom-thermal, or post-ovulation methods) is not an acceptable method of contraception. The preferred and usual lifestyle of the patient must also be evaluated in determining if sexual abstinence is a reliable method of birth control.
- •11.Be considered as reliable and capable of adhering to the protocol, according to the judgment of the investigator.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 8
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 16
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Established or suspected fibrosing colonopathy.
- •2.Total or partial gastrectomy.
- •3.A history of solid organ transplant or significant surgical resection of the bowel; significant resection of the bowel is defined as any resection of the terminal ileum or ileocecal valve. Patients who have had qualitative, long-term changes in nutritional status after any other bowel resection (eg, increased of new need for pancreatic enzyme supplementation compared with preoperative status to maintain the same nutritional status) should also be excluded.
- •4.Any chronic diarrheal illness unrelated to pancreatic insufficiency (eg, infectious gastroenteritis, sprue, inflammatory bowel disease)
- •5.Known hypersensitivity or other severe reaction to any ingredient of the investigational medicinal product (IMP).
- •6.Bilirubin > 1.5 times upper limit normal (ULN).
- •7.Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times ULN.
- •8.Alkaline phosphatase (ALP) > 5 times ULN.
- •9.Gamma glutamyltransferase (GGT) > 5 times ULN.
- •10.Signs and/or symptoms of liver cirrhosis or portal hypertension (eg, splenomegaly, ascites, esophageal varices), or documented liver disease unrelated to CF
- •11.Known allergy to the stool marker.
- •12.Feeding via an enteral tube during 6 months before screening
- •13.Routine use of anti-diarrheals, anti-spasmodics, or cathartic laxatives, or a change in chronic osmotic laxatives (eg, polyethylene glycol) regimen in the previous laxative therapy within the last 12 months before screening
- •14.History of severe constipation with < 1 evacuation/week under appropriate laxative therapy within the last 12 months before screening.
- •15.Documentation of distal intestinal pseudo-obstruction syndrome within the last 12 months before screening.
- •16.Forced Expiratory Volume < or = 30% at the screening visit.
- •17.Lactation or known pregnancy or positive pregnancy test at both screening and baseline for women of childbearing potential.
- •18.Participation in another clinical study involving an IMP within 30 days before inclusion or concomitantly with this study.
- •19.Poorly controlled diabetes according the investigator’s judgement.
研究者
相似试验
进行中（未招募）
1 期
MS1819-SD phase II clinical trial for Exocrine Pancreatic Insufficiency caused by Cystic Fibrosis.MedDRA version: 20.0Level: LLTClassification code 10033628Term: Pancreatic insufficiencySystem Organ Class: 100000004856Exocrine Pancreatic InsufficiencyEUCTR2018-003831-31-HUAzurRx24
进行中（未招募）
1 期
MS1819-SD phase II clinical trial for Exocrine Pancreatic Insufficiency caused by Cystic Fibrosis.EUCTR2018-003831-31-PLAzurRx SAS24
招募中
不适用
MS1819-SD phase IIa clinical trial for patients with exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP) and/or distal pancreatectomy.Exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP)Exocrine pancreatic insufficiency (EPI) caused by distal pancreatectomy.Metabolic and Endocrine - Other endocrine disordersOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12616000962437INC Research Australia Pty Ltd13
进行中（未招募）
不适用
A phase Ib/II, multi-center, open-label study to evaluate the efficacy of AUY922 in combination with Trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-containing regimeEUCTR2009-015628-27-FRovartis Pharma Services AG52
进行中（未招募）
不适用
A phase Ib/II, multi-center, open-label study to evaluate the efficacy of AUY922 in combination with Trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-containing regimeEUCTR2009-015628-27-SEovartis Pharma Services AG52